Clinical trials
Phase 2 Adenocarcinoma trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 4 |
| 2013 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Unknown status | 6 |
| Active, not recruiting | 4 |
| Not yet recruiting | 3 |
| Recruiting | 3 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fudan University | 3 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 3 |
| AstraZeneca | 2 |
| Ruijin Hospital | 2 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Hunan Province Tumor Hospital | 1 |
| Kunming Medical University | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Qingdao Central Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adenocarcinoma | 24 |
| Stomach Neoplasms | 6 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Prostatic Neoplasms | 3 |
| Carcinoma | 2 |
| Esophageal Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Neoplasms | 2 |
| Neoplasms, Glandular and Epithelial | 2 |
| Carcinoma, Adenoid Cystic | 1 |
Trials
Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.